Pharmacogenetic testing: not as simple as it seems

Haga, Susanne B.; Burke, Wylie

doi:10.1097/gim.0b013e31817701d4

Cited by 56 publications

(57 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A clear finding from this study, that supports previous work (Haga and Burke 2008;Netzer and Biller-Andorno 2004;Robertson 2001), was that patients being offered pharmacogenetic tests should not routinely be seen in a genetics department because of limited resources. Genetics departments are already working to capacity and referral could delay drug treatment.…”

Section: Discussionsupporting

confidence: 88%

Delivering a Pharmacogenetic Service: Is There a Role for Genetic Counselors?

Callard

Newman

Payne³

2011

Journal of Genetic Counseling

View full text Add to dashboard Cite

Pharmacogenetics, the use of genetic information to direct safer and or more effective prescription of medication, is a relatively new clinical concept. Currently, there is no consensus regarding which healthcare professionals should deliver pharmacogenetic services. This study explored the opinions of genetic counselors about their potential role in delivering pharmacogenetic services. Semi-structured face-to-face interviews were conducted with 14 genetic counselors. Four vignettes describing pharmacogenetic testing scenarios were used to elicit views on specific clinical applications. Data were analysed using the constant comparative method. Opinions varied, but the majority of interviewees suggested that genetic counselors could have a role. However, participants suggested that additional training would be needed due to counselors' limited knowledge of pharmacogenetics. Employing genetic counselors in a specialist role within a multidisciplinary clinic was suggested as a model of service delivery. Service models developed for pharmacogenetic testing may need to be adapted according to the issues presented by each type of test.

show abstract

Section: Discussionsupporting

confidence: 88%

Delivering a Pharmacogenetic Service: Is There a Role for Genetic Counselors?

Callard

Newman

Payne³

2011

Journal of Genetic Counseling

View full text Add to dashboard Cite

show abstract

“…A number of concerns have been identified that may affect uptake of PGx tests including potential for incidental information, concerns of privacy and confidentiality, and access to drugs and testing [8,11,28]. Our preliminary study adds further support for these concerns.…”

Section: Discussionsupporting

confidence: 60%

Factors Influencing Uptake of Pharmacogenetic Testing in a Diverse Patient Population

O’Daniel¹,

Lucas²,

Deverka³

et al. 2009

Public Health Genomics

View full text Add to dashboard Cite

Background: The successful integration of pharmacogenetic (PGx) testing into clinical care will require attention to patient attitudes. In this study, we aimed to identify the major reasons why patients would or would not consider PGx testing and whether these factors differed by race, socioeconomic and insurance status, and medical history. Methods: We developed and conducted a survey within the adult patient population of the Duke Family Medicine Center. Results: Of 75 completed surveys (65% African-American), 77% indicated they were ‘very likely’ or ‘somewhat likely’ to take a PGx test. Respondents who had experienced a side effect were significantly more likely to indicate they would take a PGx test and expressed greater interest in learning more about testing than those who had not. Drug safety and effectiveness were the major reasons to have PGx testing. Privacy concerns and lack of insurance coverage for testing were the major reasons to decline testing. Conclusions: We found no differences in interest in PGx tests by race or socioeconomic status, but found stronger interest from those with a history of side effects and private insurance. While the overall support of PGx testing is encouraging, greater reassurance of medical privacy and development of educational resources are needed.

show abstract

“…A limited number of articles have focused on a broad range of ethical considerations that may be more pronounced in the context of pediatric pharmacogenomics research [1, 6, 10, 19, 20]. These issues include protecting vulnerable populations, consent and assent, considerations of risks and benefits, the communication of research results, public and health professional knowledge, unintended consequences of creating therapeutic orphans, and the effect of research on the pediatric drug approval process and recruitment.…”

Section: Introductionmentioning

confidence: 99%

“…This research has the potential to optimize drug development and drug therapy and to reduce the risks of adverse drug reactions [1,2,3]. In addition, the application of pharmacogenomics promises to reduce the costs associated with health care services [4,5,6].…”

Section: Introductionmentioning

confidence: 99%

Researchers’ Perceptions of the Ethical Implications of Pharmacogenomics Research with Children

Avard

Silverstein

Sillon

et al. 2009

Public Health Genomics

View full text Add to dashboard Cite

Background: This paper presents the results of an exploratory qualitative study that assesses Canadian pediatric researchers’ perceptions of a pre-selected group of ethical issues raised by pharmacogenomics research with children. Methods: As a pilot study, we conducted semi-structured telephone interviews with Canadian pediatric pharmacogenomic researchers. The interviews were guided by the following themes: (1) benefits and risks of inclusion, (2) the consent/assent process, and (3) the return of research results. Results: Issues about assent, consent, risks and benefits, as well as the communication of results were addressed by the respondents. Some issues, such as the unique vulnerability of children, the long term privacy concerns associated with biobanking, additional core elements that need to be discussed and included in the consent/assent forms, as well as the challenges of communicating research results in a pediatric research were not explicitly identified by the respondents. Conclusion: Further consideration should be given to address the ethical challenges of including children in pharmacogenomics research. This exploratory study indicates that further guidance is needed if children are to be protected and yet benefit from such research.

show abstract

Pharmacogenetic testing: not as simple as it seems

Cited by 56 publications

References 33 publications

Delivering a Pharmacogenetic Service: Is There a Role for Genetic Counselors?

Delivering a Pharmacogenetic Service: Is There a Role for Genetic Counselors?

Factors Influencing Uptake of Pharmacogenetic Testing in a Diverse Patient Population

Researchers’ Perceptions of the Ethical Implications of Pharmacogenomics Research with Children

Contact Info

Product

Resources

About